SMPDL3B and focal segmental glomerulosclerosis: In the same study, we demonstrated that rituximab, an anti CD20 monoclonal antibody, binds to SMPDL3b, thereby stabilizing it and preventing cytoskeleton disruption and apoptosis in podocytes treated with the sera of patients with recurrent FSGS.